It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-21 15:56:42 Source:opinionsViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Brazil replaces injured goalkeeper Ederson in Copa America squad
Next:Revealed: Brit tourist, 19, subjected to sex attack in Majorca 'was gang
You may also like
- Ben Whishaw lights up the Croisette as he joins his co
- European Union official urges G7 to step up air defense for Ukraine and expand Iran sanctions
- Muslim teaching assistant claims being awarded the Christmas Grinch prize at 'light
- Denver Nuggets realize defending their NBA championship will be a tough task in improved West
- Saudi Arabia is going to sponsor the WTA women's tennis rankings under a new partnership
- Xinjiang's progress in the eyes of national legislators, political advisors
- As the aristo
- Bucks' Damian Lillard makes progress with his adductor issue before the start of the playoffs
- The government wants to buy their flood